A client with chronic kidney disease takes calcitriol for secondary hyperparathyroidism. Which laboratory result requires the nurse to hold the dose and notify the prescriber?
1Serum calcium 8.8 mg/dL and phosphorus 4.0 mg/dL
2Serum calcium 9.2 mg/dL and phosphorus 3.8 mg/dL
3Serum calcium 9.6 mg/dL and phosphorus 4.2 mg/dL
4Serum calcium 11.0 mg/dL and phosphorus 5.5 mg/dL✓ Correct answer
Explanation
Calcitriol increases intestinal calcium and phosphorus absorption. Calcium 11.0 mg/dL with phosphorus 5.5 mg/dL indicates hypercalcemia and hyperphosphatemia; their product is 60.5 mg²/dL² and the abnormal values require the medication to be held and the prescriber notified. The client needs prompt reassessment of calcitriol, calcium intake, phosphate control, and repeat laboratory monitoring.
Clinical reasoning Active vitamin D can raise both calcium and phosphorus. Excess exposure increases the risk of hypercalcemia and soft-tissue or vascular calcification.
Decision rule Hold calcitriol and escalate newly elevated calcium or phosphorus values; review calcium-phosphorus balance and the treatment plan before another dose.
Scenario 62-year-old male CKD 4 on calcitriol 0.25 mcg PO daily. Routine labs: Ca 11.0, phosphate 5.5, PTH 220.
Calcitriol — The active form of vitamin D used to increase calcium absorption and suppress excess parathyroid hormone in selected clients with kidney disease.
Calcium-phosphorus product — A calculated mineral-balance marker; excessive values increase the risk of ectopic calcification and require treatment reassessment.
Secondary hyperparathyroidism — CKD-related; treated with vit D analogs, calcimimetics, phosphate binders.